PDA

Parenteral Drug Association

InternationalInternationalIndustry association

Industry association; its Technical Reports are de-facto references for sterile and aseptic manufacturing.

Browse the standards library →Official site ↗

WHAT PDA COVERS

The Parenteral Drug Association is a non-profit association focused on sterile and parenteral manufacturing science. Its Technical Reports are detailed, peer-developed references on topics where regulatory guidance states the requirement but not the method.

WHERE IT SITS INTERNATIONALLY

PDA Technical Reports are used alongside EU GMP Annex 1, the FDA aseptic processing guidance, and USP chapters as the practical toolkit for sterile manufacturing. Their role in the hierarchy is worth being precise about: regulation states what must be achieved, guidance states what the regulator expects to see, and a Technical Report is where the industry records how it has learned to actually do it.

HOW ITS REQUIREMENTS BITE

PDA has no regulatory role. Its Technical Reports gain authority through scientific rigour and broad adoption — TR 22 on aseptic process simulation, for example, is the reference practitioners use to design media fills that satisfy Annex 1 and the FDA aseptic guidance.

WHAT PDA PUBLISHES

  1. 01Technical Report No. 22 — Process Simulation for Aseptically Filled Products
  2. 02Technical Reports on sterilisation, container closure integrity, environmental monitoring, and visual inspection
  3. 03Points to Consider documents on emerging topics
  4. 04Survey and benchmarking reports on industry practice

WHAT PRACTITIONERS GET WRONG

  • Technical Reports supply the method where Annex 1 and FDA guidance state the expectation but leave the how open.
  • TR 22 is the standard reference for media-fill design, run size, incubation, and acceptance criteria.
  • They are consensus industry documents, not regulatory requirements — cite them as supporting rationale for a chosen approach, never as the requirement itself.
  • Check the current revision; several key reports have been substantially updated following EU GMP Annex 1 (2022) and its contamination control strategy expectations.
  • An inspector will accept "we followed TR 22" only if the site can also explain why that method suits its process — the report is a starting point for justification, not a substitute for it.

PDA STANDARDS SPEQ DECODES · 1

PDA TR No. 22
Process Simulation for Aseptically Filled Products

DISCIPLINES IN PDA’S REMIT

GMPGood Manufacturing Practice
Weekly Briefing

Track PDA — and every regulator that matters

New rules, guidance, enforcement, and inspection signals from Parenteral Drug Association and its peers worldwide, distilled into the free Weekly GxP Briefing.

Read a past issue →